Regulatory, sourcing, and quality for peptide buyers.

BPC-157 sourcing guide for compounding pharmacies

A buyer-side checklist for selecting a BPC-157 supplier: COA depth, sequence verification, regulatory awareness, and how to test before you scale.

Published May 12, 2026 · 5 min read

Read briefing

Tirzepatide vs. Retatrutide: a sourcing comparison

Side-by-side on regulatory status, sourcing complexity, vial-size availability, and how to choose between the two for your compounding pipeline.

Published May 8, 2026 · 8 min read

Read briefing

Reading a peptide COA: the buyer's field guide

What every line on a Certificate of Analysis means, which fields actually matter for your application, and how to spot a doctored document.

Published May 2, 2026 · 7 min read

Read briefing

Regulatory

503A vs 503B: a peptide buyer's guide to compounding pharmacy categories

Side-by-side on the two FDA-regulated compounding pathways, eligibility, supplier qualification, documentation depth, and which path your peptide ships under.

Published May 19, 2026 · 8 min read

Read briefing

BPC-157 vs TB-500: side-by-side on chemistry, mechanism, and stack rationale

The two most-requested repair peptides compared on sequence, mechanism, analytics, and why the Wolverine Blend combines them rather than dosing them sequentially.

Published May 15, 2026 · 9 min read

Read briefing

GLP-1 class comparison: Tirzepatide, Retatrutide, Mazdutide, Survodutide

Four next-generation GLP-1-family peptides compared on receptor profile, clinical status, supply economics, and how to pick the right molecule for your research or compounding pipeline.

Published May 12, 2026 · 11 min read

Read briefing

CJC-1295 + Ipamorelin: the dual-pathway GH-axis blend explained

Why the canonical GH-axis blend works mechanistically, how the components differ, what ratio matters in practice, and the analytics that distinguish a clean blend from a sloppy one.

Published May 10, 2026 · 10 min read

Read briefing

Formulating with GHK-Cu: the cosmetic OEM guide

What to do (and not do) when incorporating GHK-Cu copper tripeptide into a finished cosmetic product, stability, pH, chelator compatibility, and the analytical checks that confirm the active is still active.

Published May 6, 2026 · 8 min read

Read briefing

Peptide counter-ions: why acetate beats TFA for most downstream uses

What the counter-ion is, why most synthetic peptides ship as either acetate or TFA salt, how to tell which you have, and why downstream pharmaceutical and assay work strongly prefers acetate.

Published May 4, 2026 · 6 min read

Read briefing

How to qualify a China-based peptide supplier: a buyer's vetting checklist

Six concrete checks that distinguish a serious China-based peptide manufacturer from a paper-only middleman, documentation depth, analytical transparency, regulatory awareness, and supply continuity.

Published May 14, 2026 · 10 min read

Read briefing

Peptide OEM manufacturing: the end-to-end workflow from inquiry to commercial production

Six stages of the OEM peptide workflow, RFQ, NDA and quote, sample synthesis, formulation/packaging development, commercial production, and recurring-order operations. Timeline, deliverables, and what each stage actually involves.

Published May 13, 2026 · 11 min read

Read briefing

Bulk peptide pricing demystified: MOQ, lead time, and the economics behind your quote

Why bulk peptide pricing varies 10× across suppliers for the same molecule, what drives the cost stack, how MOQ and lead time interact with price, and what break points actually matter in your procurement strategy.

Published May 18, 2026 · 12 min read

Read briefing

Endotoxin (LAL) testing for injectable peptides: USP <85> and what your COA should show

What endotoxin contamination is, why it confounds peptide research and clinical readouts, how the LAL test works, what specifications to ask for on your COA, and which peptides need the test most.

Published May 16, 2026 · 9 min read

Read briefing

The med-spa peptide buyer's playbook: GHK-Cu, B-12, lipotropics, and OEM brands

Med-spa peptide procurement is different from compounding pharmacy or research-lab buying. This guide covers the workhorse SKUs, the OEM finished-product pathway, INCI naming and CPNP notification, and the regulatory landscape specific to aesthetic medicine.

Published May 14, 2026 · 10 min read

Read briefing

Regulatory

Tirzepatide compounding shortage: where the regulatory state stands in 2026

FDA's evolving position on compounded Tirzepatide, the October 2024 removal from the drug-shortage list, the late-2024 court rulings, and what compounding-pharmacy buyers need to know about sourcing and dispensing today.

Published May 11, 2026 · 10 min read

Read briefing

Solid-phase peptide synthesis (SPPS): the chemistry behind every catalog peptide

How Fmoc-strategy SPPS actually works, why cycle yield matters more than total yield, where common side-reactions originate, and what the analytical packet tells you about synthesis quality.

Published April 28, 2026 · 12 min read

Read briefing

HPLC method development for peptide purity and identity: what your analytical chemist actually does

How reverse-phase HPLC methods are developed for peptide analysis, why method development matters more than ready-made protocols, and what an ≥99% purity number really tells you.

Published May 1, 2026 · 11 min read

Read briefing

Mass spectrometry for peptide identity: ESI mass spec vs LC-MS/MS sequence verification

ESI mass spec confirms molecular weight to within 0.5 Da; LC-MS/MS confirms the sequence at the residue level. Why the second test matters for any peptide above 15 residues and what the b/y-ion ladder actually shows.

Published May 3, 2026 · 12 min read

Read briefing

Peptide stability kinetics: accelerated vs real-time studies, and what the Arrhenius equation predicts

How peptide stability programs are designed, what accelerated 40°C/75%RH studies do and don't tell you, why some degradation pathways aren't Arrhenius-compliant, and what stability data your COA should show.

Published May 5, 2026 · 11 min read

Read briefing

Top peptides for tissue repair research: 8 SKUs ranked by mechanism and research evidence

BPC-157, TB-500, GHK-Cu, Wolverine Blend, B7-33, IGF-1 LR3, MGF, and ARA-290 compared for tissue-repair research. Mechanism, research context, analytical considerations, and how to choose between them.

Published May 7, 2026 · 9 min read

Read briefing

Top peptides for cosmetic and dermal formulation: 7 SKUs for OEM brands and med-spa programs

GHK-Cu, Snap-8, Matrixyl, AHK-Cu, Melatonin, Glutathione, and Lipo-C compared for cosmetic and dermal-aesthetic formulation. INCI naming, formulation considerations, regulatory framework, and use-case fit.

Published May 9, 2026 · 10 min read

Read briefing

Top peptides for cognitive and neuro research: 8 SKUs across cognitive enhancement, anxiolytic, sleep, and neuroprotection

Semax, Selank, DSIP, Kisspeptin-10, Pinealon, P21, VIP, and PNC-27 compared for cognitive and neuro research. Mechanism, administration route, research evidence, and how to select for specific experimental questions.

Published May 11, 2026 · 10 min read

Read briefing

Cosmetic peptide comparison: GHK-Cu vs AHK-Cu vs Snap-8 vs Matrixyl

Four most-procured cosmetic peptides compared on mechanism, INCI naming, typical use level, formulation compatibility, and which targets which cosmetic claim. A buyer's decision matrix for OEM brand formulators.

Published May 19, 2026 · 10 min read

Read briefing

GHRH analog comparison: CJC-1295 vs Sermorelin vs Tesamorelin

Three GHRH-receptor agonists compared on engineering, half-life, regulatory pedigree, and best application. Why each occupies a distinct niche despite shared mechanism, and how to choose.

Published May 17, 2026 · 10 min read

Read briefing